小鼠对HIV-2 gp105核酸疫苗免疫应答的研究

目的: 探讨HIV- 2gp105基因核酸疫苗在小鼠体内的免疫应答, 为开发HIV- 2核酸疫苗提供实验依据。方法:将HIV- 2外膜蛋白 (gp105 )基因插入真核表达质粒载体pVAX1中, 构建pVAX1 gp105重组表达质粒。将其肌注免疫BALB/c小鼠, 用ELISA法检测小鼠血清抗HIV -2抗体, 用流式细胞仪测定CD4 、CD8 T细胞亚群数, 以乳酸脱氢霉释放法检测脾特异性CTL的杀伤活性。结果: 重组质粒pVAX1 -gp105免疫组小鼠的血清抗体滴度、脾T细胞亚群的数量及特异性CTL的杀伤活性, 均明显高于对照组, 分别为P<0. 01, P<0. 05和P<0. 01。结论: HIV -2gp105核酸疫苗能诱导小鼠产生特异性细胞和体液免疫。

Immune response to HIV-2 gp105 DNA vaccine in mice

AIM: To explore the immune response of mice vaccinated with HIV-2 gp105 nucleic acid vaccine. METHODS: pVAX1-gp105 recombinant DNA vaccine was constructed by inserting HIV-2 gp105 cDNA into an eukaryotic expression vector pVAX1. BALB/c mice were immunized with pVAX1-gp105, pVAX1 and PBS, respectively via intramuscular injection. Anti-HIV-2 antibody was detected by ELISA. The percentages of CD4 and CD8 T cell subsets from immunized mice were analyzed by flow cytometry and the specific killing activity of splenic CTLs was measured by lactate dehydrogenase (LDH) release assay. RESULTS: The titer of specific antibody, the numbers of CD4 and CD8 T cells and cytotoxic activity of specific CTLs in pVAX1-gp105 vaccination group were obviously higher than those in control group (P<0.01, P<0.05 and P<0.01, respectively). CONCLUSION: pVAX1-gp105 nucleic acid vaccine can elicit specific cellular and humoral immunities in mice.